Bioventus (NASDAQ: BVS) revenue
Bioventus reported revenue of $568.1m for fiscal 2025, 0.9% less than in fiscal 2024 ($573.3m). Since fiscal 2020 its revenue has grown by 76.9%, an average growth of 12.1% a year.
Bioventus's best year of the last 6 was fiscal 2024. The biggest drop was in fiscal 2025, −0.9%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $568.1m | −0.9% | $54.0m | 9.5% |
| 2024 | $573.3m | +11.9% | −$15.2m | −2.7% |
| 2023 | $512.3m | 0.0% | −$81.7m | −16.0% |
| 2022 | $512.1m | +18.8% | −$167.2m | −32.7% |
| 2021 | $430.9m | +34.2% | $12.1m | 2.8% |
| 2020 | $321.2m | — | $21.2m | 6.6% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Bioventus revenue compared with its sector
By revenue for its latest fiscal year, Bioventus ranks 187th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Bioventus, −0.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 185th | UFP Technologies | $602.8m | 19.5% |
| 186th | Azenta | $593.8m | 3.6% |
| 187th | Bioventus | $568.1m | −0.9% |
| 188th | AtriCure | $534.5m | 14.9% |
| 189th | Mirum Pharmaceuticals | $521.3m | 54.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Bioventus
- How much revenue did Bioventus make in fiscal 2025?
- Bioventus reported revenue of $568.1m for fiscal 2025, compared with $573.3m in fiscal 2024.
- How much has the revenue of Bioventus grown?
- Between fiscal 2020 and fiscal 2025 it went from $321.2m to $568.1m: 76.9% more, an average growth of 12.1% a year.
- What was the best year for revenue at Bioventus?
- Of its last 6 fiscal years, fiscal 2024, with $573.3m.
- Where does Bioventus rank in its sector by revenue?
- It ranks 187th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Bioventus come from?
- From the annual report (Form 10-K) that Bioventus files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Bioventus files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Bioventus: the Bioventus page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.